Sign Out
Prostate cancer: Treatment of locally advanced or metastatic, hormone-dependent prostate cancer.
As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.
Endometriosis.
Central precocious puberty (before 8 years in girls and 10 years in boys).
3.75 mg: Treatment of uterine fibromyomas prior to surgery.
Breast cancer: As adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in women at high risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy.
